Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Allakos Inc. (ALLK)

ALLK

NEW YORK, NY / ACCESSWIRE / February 17, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allakos Inc. ("Allakos" or the "Company") (NASDAQ:ALLK). Investors who purchased Allakos securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/allk.

The investigation concerns whether Allakos and certain of its officers and/or directors have violated federal securities laws.

On December 18, 2019, Seligman Research ("Seligman") published a report characterizing Allakos as "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud." Among a litany of other issues, the Seligman report accused Allakos of having "buried the results for the two AK001 studies it conducted, but our research indicates a debacle"; having "a checkered history of conducting small, low-credibility trials, marked by a striking level of what we consider to be discrepancies, omissions, cherry-picking, and other red flags"; and engaging in "[f]lagrant nepotism in key clinical roles". Following this news, Allakos's stock price fell $13.25 per share, or 10%, to close at $119.28 on December 18, 2019.

If you are aware of any facts relating to this investigation, or purchased Allakos shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/allk. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/576562/Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation-Allakos-Inc-ALLK